Liu J., Killilea D. W., Ames B. N.
Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):1876–81. doi:10.1073/pnas.261709098.Liu J, et al.
Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NY Acad Sci. 2002 Apr;959:133– 66. doi:10.1111/j.1749–6632.2002.tb02090.x.Liu J., et al.
Memory loss in old rats is associated with brain mitochondrial decay and RNA/ DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha- lipoic acid. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):2356–61. doi:10.1073/pnas.261709299.Meydani M., et al.
The effect of long-term dietary supplementation with antioxidants. Ann NY Acad Sci. 1998 Nov 20; 854:352–60. doi:10.1111/j.1749–6632.1998.tb09915.Nyengaard J. R., et al.
Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes. 2004 Nov; 53(11):2931–8. doi:10.2337/diabetes.53.11.2931.Scott B. C., et al.
Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res. 1994 Feb; 20(2):119–33. doi:10.3109/10715769409147509.Tappel A., Fletcher B., Deamer D.
Effect of antioxidants and nutrients on lipid peroxidation fluorescent products and aging parameters in the mouse. J Gerontol. 1973 Oct; 28(4):415–24. doi:10.1093/geronj/28.4.415. Thornalley P. J. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002; 50:37–7. doi:10.1016/S0074-7742(02)50072-6.Williamson J. R., et al.
Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993 Jun; 42(6):801–13. doi:10.2337/diab.42.6.801. Ziegler D., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb; 21(2):114–21. doi:10.1111/j.1464–5491.2004.01109.Zhou L., et al.
α-Lipoic acid ameliorates mitochondrial impairment and reverses apoptosis in FABP3-overexpressing embryonic cancer cells. J Bioenerg Biomembr. 2013 Oct;45(5): 459–66. Epub 2013 Mar 28.Креатин
Andrews R., et al.
The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J. 1998 Apr; 19(4):617–22.Balestrino M., et al.
Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids. 2002; 23(1–3):221–9. doi:10.1007/s00726-001-0133-3.Broqvist M., et al.
Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure — effects of long-term dietary supplementation. Eur Heart J. 1994 Dec;15(12):1641–50. doi:10.1093/ oxfordjournals.eurheartj.a060447.Ferrante R. J., et al.
Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci. 2000 Jun 15;20(12):4389–97. Field M. L. Creatine supplementation in congestive heart failure [letter]. Cardiovasc Res 1996 Jan; 31(1):174–6.Gordon A., et al.
Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res. 1995 Sep; 30(3):413–8.Klivenyi P., et al.
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999 Mar; 5(3):347–50. doi:10.1038/6568.Malcon C., Kaddurah-Daouk R., Beal M. F.
Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. 2000 Mar 31; 860(1–2):195–8. doi:10.1016 /S0006-8993(00)02038-2.Matthews R. T., et al.
Neuroprotective effects of creatine and cyclocre-atine in animal models of Huntington’s disease. J Neurosci. 1998 Jan; 18(1):156–63.Matthews R. T., et al.
Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999 May; 157(1):142–9. doi:10.1006/exnr.1999.7049. Park J. H., et al. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum. 1998 Mar; 41(3):406–13. doi:10.1002/1529-0131(199803)41:3<406::AID-ART5>3.0.CO;2-L.Tarnopolsky M., Martin J.
Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology. 1999 Mar 10; 52(4):854–7.Walter M. C., et al.
Creatine monohydrate in muscular dystrophies: a double blind, placebo-controlled clinical study. Neurology. 2000 May 9; 54(9):1848–50.Витамины группы В